Pharma giant BMS sees big things in the field of biologics, having already invested €1bn in a state-of-the-art Irish facility.

For Bristol-Myers Squibb (BMS), there is an immense interest in the field of biologics given its base here in Ireland and the country’s huge profile of academic and pharmaceutical links to it.

Speaking at BioPharma Ambition, Mairead Looby, director of manufacturing science and technology at BMS, said it was a very exciting time for the company, especially given its recent construction of a €1bn state-of-the-art biologics facility at Cruiserath.

“That facility will manufacture really life-saving medicines,” she said in conversation with

“A lot of the immuno-oncology that BMS makes will be made in that facility in the future.”


Words by Colm Gorey